Tobramycin iontophoresis into corneas infected with drug-resistant Pseudomonas aeruginosa.
Iontophoretic application of tobramycin was used to deliver drug to the cornea of rabbit eyes infected with a tobramycin-resistant strain of Pseudomonas aeruginosa (MIC = 31.25 micrograms/ml). Corneas infected with P. aeruginosa 27853/pMG6 were treated 22 hours after infection with tobramycin delivered by either iontophoresis, mock iontophoresis (eye cup without current), or application of fortified topical drops. Corneal iontophoresis of tobramycin at 25 mg/ml caused more than a three log reduction in bacteria; yielding a significantly lower number of bacteria compared to untreated controls and all other treatments (P less than or equal to 0.0001). Corneal iontophoresis of tobramycin at 10 mg/ml showed a one log reduction in the number of bacteria per cornea, yielding a significantly lower number of bacteria compared to untreated controls (P less than or equal to 0.0001), corneas treated with nine topical applications of 1.36% tobramycin drops (P less than or equal to 0.0001), and corneas treated with mock iontophoresis (P less than or equal to 0.02). These results suggest that iontophoresis is a powerful ocular delivery system for tobramycin and may be suitable for use with other chemotherapeutic agents.
Hobden
J A
JA
Department of Microbiology, Immunology, and Parasitology, Louisiana State University Medical Center School of Medicine, New Orleans 70112.
O'Callaghan
R J
RJ
Hill
J M
JM
Reidy
J J
JJ
Rootman
D S
DS
Thompson
H W
HW
D000287:Administration, Topical; D000818:Animals; D003227:Conjugation, Genetic; D003315:Cornea / Q000382:microbiology; D004352:Drug Resistance, Microbial; D015818:Eye Infections, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D007478:Iontophoresis; D007634:Keratitis / Q000188:drug therapy* / Q000382:microbiology; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification; D011815:R Factors; D011817:Rabbits; D011897:Random Allocation; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use*
D014031:Tobramycin